Androgen receptor in human normal and malignant pancreatic tissue and cell lines
β Scribed by Timothy P. Corbishley; M. Jawed Iqbal; Mark L. Wilkinson; Roger Williams
- Publisher
- John Wiley and Sons
- Year
- 1986
- Tongue
- English
- Weight
- 420 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
BACKGROUND. The presence of neuroendocrine (NE) differentiation in benign and neoplastic prostate tissue has attracted increasing attention in contemporary prostate cancer research. METHODS. The present review focuses on the proliferation and androgen receptor (AR) status of NE phenotypes and their
Thyroid carcinomas no longer accessible to radio-iodide or TSH-suppressive T4 therapy, due to loss of thyroid-specific functions, might be sufficiently re-differentiated by retinoic acid (RA) to be treated by conventional methods again. To help evaluate the feasibility of RA re-differentiation thera
Specific endothelin-1 (ET1) binding sites have been demonstrated in membranes derived from normal (NP) and benign hyperplasic (BPH) human prostate using an lZ5I-ETl binding assay. '=I saturation experiments and Scatchard analysis demonstrated the existence of a homogeneous population of binding site
While androgens have important skeletal effects, the mechanism(s) of androgen action on bone remain unclear. Current osteoblast models to study androgen effects have several limitations, including the presence of heterogeneous cell populations. In this study, we examined the effects of androgens on
Progression to androgen independence remains the main problem that impacts on survival and quality of life in prostate cancer patients. We have investigated the potency of tributyrin, an orally available prodrug of butyrate, to induce growth arrest, differentiation and apoptosis in LNCaP, PC-3 and T